drugset / Trial / NCT00414466

A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain

NCT00414466

Phase 2 Terminated 254 enrolled MedtronicNeuro
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and minimum effective dose of intraspinal gabapentin when delivered through an implanted drug infusion system.

Timeline

Start
2006-12
Primary completion
2009-12
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gabapentin Small molecule 1 mg Intrathecal
Comparator Gabapentin Small molecule 6 mg Intrathecal
Comparator Gabapentin Small molecule 30 mg Intrathecal

Indications